Skip to main content
Clinical Trials/NCT06498115
NCT06498115
Recruiting
Phase 4

Effect of Prophylactic Intravenous Norepinephrine Infusion on Maternal Hypotension After Combined Lumbar and Epidural Anaesthesia for Caesarean Section

The Third People's Hospital of Bengbu1 site in 1 country100 target enrollmentJuly 2024

Overview

Phase
Phase 4
Intervention
Norepinephrine
Conditions
Maternal Hypotension
Sponsor
The Third People's Hospital of Bengbu
Enrollment
100
Locations
1
Primary Endpoint
Intravenous norepinephrine to maintain maternal systolic blood pressure 80% above baseline before fetal delivery.
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Norepinephrine has emerged as a potential alternative for stabilizing blood pressure during spinal anesthesia for cesarean section, purportedly maintaining maternal heart rate and cardiac output more effectively than phenylephrine. However, its application as an intravenous bolus for treating hypotension remains underexplored. Consequently, this current investigation aimed to determine the ED50 and ED95 of norepinephrine for managing maternal hypotension during cesarean section. A prospective trial enrolled 100 patients undergoing elective delivery under spinal anesthesia, with norepinephrine dosage determined using the upper and lower sequential distribution method (UDM).

Registry
clinicaltrials.gov
Start Date
July 2024
End Date
December 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
The Third People's Hospital of Bengbu
Responsible Party
Principal Investigator
Principal Investigator

Chengfei Xu

doctor-in-charge

The Third People's Hospital of Bengbu

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria included women undergoing elective caesarean section undergoing combined lumbar and rigid anaesthesia, healthy singleton pregnancies at full term (more than 37 weeks gestation), American Society of Anaesthesiologists physical status I or II, body weight between 50-100 kg, height between 150-180 cm, and fasting for more than 8 hours.

Exclusion Criteria

  • The exclusion criteria included individuals with hypertension, cardiovascular diseases, preeclampsia, arrhythmias, diabetes mellitus, spinal cord malformations, abnormal fetal conditions, and those who declined to participate in the study.

Arms & Interventions

Norepinephrine Bolus

Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.

Intervention: Norepinephrine

Outcomes

Primary Outcomes

Intravenous norepinephrine to maintain maternal systolic blood pressure 80% above baseline before fetal delivery.

Time Frame: From the initiation of anesthesia to the delivery of the fetus.

Intravenous norepinephrine pumped to maintain maternal systolic blood pressure 80% above its basal value prior to delivery of the foetus

Secondary Outcomes

  • Neonatal Apgar score(Immediately After delivery of the foetus)
  • Intraoperative adverse reactions(Perioperative period)
  • Number of remedial drugs(Perioperative period)

Study Sites (1)

Loading locations...

Similar Trials